Biologic Drugs With Mechanism of Action: CD20-directed Antibody Interactions
✉ Email this page to a colleague
Biologic Drugs With Mechanism of Action: CD20-directed Antibody Interactions
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 1997-11-26 | ⤷ Subscribe | ⤷ Subscribe |
Novartis Pharmaceuticals Corporation | ARZERRA | ofatumumab | Injection | 125326 | 2009-10-26 | ⤷ Subscribe | ⤷ Subscribe |
Genentech, Inc. | GAZYVA | obinutuzumab | Injection | 125486 | 2013-11-01 | ⤷ Subscribe | ⤷ Subscribe |
Genentech, Inc. | OCREVUS | ocrelizumab | Injection | 761053 | 2017-03-28 | ⤷ Subscribe | ⤷ Subscribe |
Genentech, Inc. | RITUXAN HYCELA | rituximab and hyaluronidase human | Injection | 761064 | 2017-06-22 | ⤷ Subscribe | ⤷ Subscribe |
Celltrion, Inc. | TRUXIMA | rituximab-abbs | Injection | 761088 | 2018-11-28 | ⤷ Subscribe | ⤷ Subscribe |
Pfizer Ireland Pharmaceuticals | RUXIENCE | rituximab-pvvr | Injection | 761103 | 2019-07-23 | ⤷ Subscribe | ⤷ Subscribe |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Patent Expiration |